

DAFTAR PUSTAKA

1. Weerakoon H, Vithanage I, Alahakoon O, Weerakoon K. Clinico-epidemiology and Aetiopathogenesis of Gallstone Disease in the South Asian Region: A Scoping Review Protocol. 2022;1–3.
2. Ansari-Moghaddam A, Khorram A, Miri-Bonjar M, Mohammadi M, Ansari H. The Prevalence and Risk Factors of Gallstone Among Adults in South-East of Iran: A Population-Based Study. *Glob J Health Sci*. 2015;8(4):60–7.
3. Su Z, Gong Y, Liang Z. Prevalence of Gallstone in Mainland China: A Meta-Analysis of Cross-Sectional Studies. *Clin Res Hepatol Gastroenterol*. 2020 Sep 1;44(4):e69–71.
4. Anbiar MAP, Suchitra A, Desmawati D. The Hubungan Obesitas dengan Kejadian Kolelitiasis di RSUP Dr. M. Djamil Padang Periode Januari – Desember 2019. *J Ilmu Kesehat Indones*. 2022;2(2):65–73.
5. Kereh DS, Lampus H, Sapan HB, Loho LL. Hubungan Antara Jenis Batu dan Perubahan Mukosa Kandung Empedu pada Pasien Batu Kandung Empedu. *J Biomedik*. 2015;7(3):41–7.
6. Di Ciaula A, Wang DQH, Portincasa P. An Update on the Pathogenesis of Cholesterol Gallstone Disease. *Curr Opin Gastroenterol*. 2018 Mar 1;34(2):71.
7. Yova Meidina TR, Mudjihartini N, Gunarti DR, Yulhasri Y, Dewi S, Hardiany NS. Analisis Komposisi dan Distribusi Batu Empedu di Laboratorium Fakultas Kedokteran Universitas Indonesia (FKUI) Jakarta. *J Biotek Medisiana Indones*. 2020;9(1):19–26.
8. Lonardo A, Nascimbeni F, Ballestri S, Fairweather DL, Win S, Than TA, et al. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. *Hepatology*. 2019 Oct 1;70(4):1457–69.
9. Wang H, So H, Ko SW, Jung SW, Bang SJ, Park EJ. Gallstone is Associated with Metabolic Factors and Exercise in Korea. *Healthcare*. 2022 Aug 1;10(8).
10. Lamberts MP, Den Oudsten BL, Gerritsen JJGM, Roukema JA, Westert GP, Drenth JPH, et al. Prospective Multicentre Cohort Study of Patient-reported Outcomes after Cholecystectomy for Uncomplicated Symptomatic Cholelithiasis. *Br J Surg*. 2015;102(11):1402–9.
11. Peksen C, Aktokmakyar T V., Savas OA, Ediz B, Sumer A. Comparison of Laparoscopic Evaluation of Hepatosteatosi with Ultrasound Findings. *Eur Rev Med Pharmacol Sci*. 2023;27(19):9067–75.
12. Hassler KR, Collins JT, Philip K, Jones MW. Laparoscopic

Cholecystectomy. StatPearls [Internet]. 2022 Oct 24 [cited 2023 Mar 2]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK448145/>

13. Tanaka N, Ichijo T, Okiyama W, Mutou H, Misawa N, Matsumoto A, et al. Laparoscopic Findings in Patients with Nonalcoholic Steatohepatitis. *Liver Int.* 2006 Feb;26(1):32–8.
14. Pathology RB, Pathology RE. *Pathologic Basis of Disease*. 10th ed. Kumar V, K. Abbas A, C. Aster J, editors. Canada: Jeremy Bowes; 2021. 823–45 p.
15. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The Prevalence and Incidence of NAFLD Worldwide: a Systematic Review and Meta-analysis. *lancet Gastroenterol Hepatol.* 2022 Sep 1;7(9):851–61.
16. Kichloo A, Solanki S, Haq KF, Dahiya D, Bailey B, Solanki D, et al. Association of Non-alcoholic Fatty Liver Disease with Gallstone Disease in the United States Hospitalized Patient Population. *World J Gastrointest Pathophysiol.* 2021 Mar 3;12(2):14.
17. Ruhl CE, Everhart JE. Relationship of Non-alcoholic Fatty Liver Disease with Cholecystectomy in the US Population. *Am J Gastroenterol.* 2013 Jun;108(6):952–8.
18. de Aguiar RGP, de Souza Junior FEA, Rocha Júnior JLG, Pessoa FSR de P, da Silva LP, Do Carmo GC. Clinical and Epidemiological Evaluation of Complications Associated with Gallstone in a Tertiary Hospital. *Arq Gastroenterol.* 2022 Jul 1;59(3):352–7.
19. Gallstone Disease [Internet]. [cited 2023 Feb 8]. Available from: https://www.hopkinsmedicine.org/gastroenterology_hepatology/_docs/_pdfs/pancreas_biliary_tract/gallstone_disease.pdf
20. Ha BJ, Park S. Classification of Gallstones Using Fourier-transform infrared Spectroscopy and Photography. *Biomater Res.* 2018 Jul 18;22(1).
21. Wang Q, Hao C, Yao W, Zhu D, Lu H, Li L, et al. Intestinal Flora Imbalance Affects Bile Acid Metabolism and is Associated with Gallstone Formation. *BMC Gastroenterol.* 2020 Mar 6;20(1).
22. Chang YR, Jang JY, Kwon W, Park JW, Kang MJ, Ryu JK, et al. Changes in demographic features of gallstone disease: 30 years of surgically treated patients. *Gut Liver.* 2013;7(6):719–24.
23. Hakim A. Gambaran Kasus Kolelitiasis di Rumah Sakit Umum Daerah Palembang Bari Tahun 2017. 2017; Available from: <http://repository.um-palembang.ac.id/id/eprint/2783/>
24. Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall HU. Genetic and Environmental Influences on Symptomatic Gallstone Disease: a Swedish Study of 43,141 Twin Pairs. *Hepatology.* 2005

May;41(5):1138–43.

25. Di Ciaula A, Wang DQH, Bonfrate L, Portincasa P. Current Views on Genetics and Epigenetics of Cholesterol Gallstone Disease. *Cholesterol*. 2013;2013:1–6.
26. Pak M, Lindseth G. Risk Factors for Cholelithiasis. *Gastroenterol Nurs*. 2016;39(4):297–309.
27. Cirillo DJ, Wallace RB, Rodabough RJ, Greenland P, LaCroix AZ, Limacher MC, et al. Effect of Estrogen Therapy on Gallbladder Disease. *JAMA*. 2005 Jan 19;293(3):330–9.
28. Stender S, Nordestgaard BG, Tybjærg-Hansen A. Elevated Body Mass Index as a Causal Risk Factor for Symptomatic Gallstone Disease: a Mendelian Randomization Study. *Hepatology*. 2013 Dec;58(6):2133–41.
29. Yuan S, Gill D, Giovannucci EL, Larsson SC. Obesity, Type 2 Diabetes, Lifestyle Factors, and Risk of Gallstone Disease: A Mendelian Randomization Investigation. *Clin Gastroenterol Hepatol*. 2022 Mar 1;20(3):e529–37.
30. Shell A cruce. *Introduction to Human Physiology*. 8th ed. Alexander S, Glubka A, Crosby L, editors. Yolanda Cossio; 2016. 1–23 p.
31. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Macronutrients and Insulin Resistance in Cholesterol Gallstone Disease. *Am J Gastroenterol*. 2008 Nov;103(11):2932–9.
32. Stolk MFJ, Van Erpecum KJ, Renooij W, Portincasa P, Van De Heijning BJM, VanBerge-Henegouwen GP. Gallbladder Emptying in Vivo, Bile Composition, and Nucleation of Cholesterol Crystals in Patients with Cholesterol Gallstones. *Gastroenterology*. 1995;108(6):1882–8.
33. Shabanzadeh DM, Sørensen LT, Jørgensen T. Determinants for Gallstone Formation – a New Data Cohort Study and a Systematic Review with Meta-analysis*. *Scand J Gastroenterol*. 2016 Oct 2;51(10):1239–48.
34. Chang L, Chang M, Chang HM, Chang AI, Chang F. Clinical and Radiological Diagnosis of Gallstone Ileus: a Mini Review. *Emerg Radiol*. 2018 Apr 1;25(2):189–96.
35. Gagola PCD, Timban JFJ, Ali RH. Gambaran Ultrasonografi Batu Empedu Pada Pria & Wanita Di Bagian Radiologi Fk Unsrat Blu Rsup Prof. Dr. R. D. Kandou Manado Periode Oktober 2012- Oktober 2014. *e-CliniC*. 2015;3(1):429–30.
36. Hjaltadóttir K, Haraldsdóttir KH, Möller PH. Gallstones - Review. *Laeknabladid*. 2020;106(10):464–72.

37. Ayu D, Novista V. Non-alcoholic Fatty Liver Disease : Diagnosis and Treatment. *Biol Trop*. 2023;23(3):213–24.
38. Atamanalp SS, Yildirgan MI, Kantarci A. Endoscopic Retrograde Cholangiopancreatography (ERCP): Outcomes of 3136 Cases Over 10 Years. *Turkish J Med Sci*. 2011;41(4):615–21.
39. Wirth J, Joshi AD, Song M, Lee DH, Tabung FK, Fung TT, et al. A Healthy Lifestyle Pattern and the Risk of Symptomatic Gallstone Disease: Results From 2 Prospective Cohort Studies. *Am J Clin Nutr*. 2020 Aug 1;112(3):586.
40. Littlefield A, Lenahan C. Cholelithiasis: Presentation and Management. *J Midwifery Womens Health*. 2019 May 1;64(3):289–97.
41. Pineda O, Maydón HG, Amado M, Sepúlveda EM, Guilbert L, Espinosa O, et al. A Prospective Study of the Conservative Management of Asymptomatic Preoperative and Postoperative Gallbladder Disease in Bariatric Surgery. *Obes Surg*. 2017 Jan 1;27(1):148–53.
42. Martino D, Bonito C. Conservative Management of Gallstone Disease in the Elderly Population: Outcomes and Recurrence. *Scand J Surg*. 2019;2020(3):205–10.
43. Contraindications and Complications of Laparoscopic Cholecystectomy - PubMed [Internet]. [cited 2023 Feb 8]. Available from: <https://pubmed.ncbi.nlm.nih.gov/7977000/>
44. Teoh AY. Gallstones. *Niger J Surg Off Publ Niger Surg Res Soc*. 2013 Jan 1;19(2):49.
45. Wang HH, Portincasa P, de Bari O, Liu KJ, Garruti G, Neuschwander-Tetri BA, et al. Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol. *Eur J Clin Invest*. 2013;43(4):413–26.
46. Bedogni G, Nobili V, Tiribelli C. Epidemiology of Fatty Liver: An Update. *World J Gastroenterol*. 2014 Jul 7;20(27):9050.
47. Park H, Yoon EL, Kim M, Kim JH, Cho S, Jun DW, et al. Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver. *J Clin Med*. 2021 Oct 1;10(19).
48. Raza S, Rajak S, Upadhyay A, Tewari A, Sinha RA. Current Treatment Paradigms and Emerging Therapies for NAFLD/NASH. *Front Biosci (Landmark Ed)*. 2021 Jan 1;26(2):206–37.
49. Raman M, Allard J. Nonalcoholic Fatty Liver Disease: A Clinical Approach and Review. *Can J Gastroenterol*. 2006;20(5):345.

50. Powell EE, Wong VWS, Rinella M. Non-Alcoholic Fatty Liver Disease. *Lancet* (London, England). 2021 Jun 5;397(10290):2212–24.
51. Amarpurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How Common is Non-Alcoholic Fatty Liver Disease in the Asia–Pacific Region and are there Local Differences? *J Gastroenterol Hepatol*. 2007 Jun 1;22(6):788–93.
52. Astari NA, Decroli E, Yerizel E. Gambaran NAFLD pada Pasien dengan Sindrom Metabolik di Poliklinik Penyakit Dalam RSUP Dr. M. Djamil Padang. *Andalas*. 2015;4(2).
53. Abbas N, Makker J, Abbas H, Balar B. Perioperative Care of Patients with Liver Cirrhosis: A Review. *Heal Med J*. 2017 Feb 24;10.
54. Li B, Zhang C, Zhan YT. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. *Can J Gastroenterol Hepatol*. 2018;2018.
55. DiStefano JK. NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. *Endocrinology*. 2020 Oct 1;161(10).
56. Rasyid MFA. Pengaruh Asupan Kalsium Terhadap Indeks Masa Tubuh (IMT). *J Med Utama*. 2021;2(4):1095–7.
57. Della Corte C, Mazzotta AR, Nobili V. Fatty liver disease and obesity in youth. *Curr Opin Endocrinol Diabetes Obes*. 2016;23(1):66–71.
58. Buzzetti E, Pinzani M, Tsochatzis EA. The Multiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD). *Metabolism*. 2016 Aug 1;65(8):1038–48.
59. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of Nonalcoholic Fatty Liver Disease with Insulin Resistance. *Am J Med*. 1999 Nov;107(5):450–5.
60. Zou CC, Liang L, Hong F, Fu JF, Zhao ZY. Serum Adiponectin, Resistin Levels and Non-Alcoholic Fatty Liver Disease in Obese Children. *Endocr J*. 2005;52(5):519–24.
61. Mekanisme Resistensi Insulin Terkait Obesitas [Internet]. [cited 2023 Jan 11]. Available from: <https://akper-sandikarsa.e-journal.id/JIKSH/article/view/190/162>
62. Tsao TS, Lodish HF, Fruebis J. ACRP30, a New Hormone Controlling Fat and Glucose Metabolism. *Eur J Pharmacol*. 2002 Apr 12;440(2–3):213–21.
63. Paleva Rheza. Literatur Review Mekanisme Resistensi Insulin Terkait Obesitas. *Insul Resist Mech Relat to Obesity*. 2019;10(2):354–8.

64. Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, et al. Racial and Ethnic Distribution of Nonalcoholic Fatty Liver in Persons with Newly Diagnosed Chronic Liver Disease. *Hepatology*. 2005 Feb;41(2):372–9.
65. Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. 2021;1–9.
66. Antunes C, Azadfard M, Hoilat GJ, Gupta M. Fatty Liver. *StatPearls* [Internet]. 2022 Oct 24 [cited 2023 Feb 3]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK441992/>
67. NAFLD – diagnosis, assessment and management - The British Society of Gastroenterology [Internet]. [cited 2023 Feb 3]. Available from: <https://www.bsg.org.uk/web-education-articles-list/nafl-d-diagnosis-assessment-and-management/>
68. Tjiptaningrum A. *Aspek Klinis dan Laboratorium pada Gangguan Gastrointestinal dan Hepatobilier*. Bandar Lampung: CV. Anugrah Utama Raharja; 2019. 1–50 p.
69. Ibacache C, Correa-Burrows P, Burrows R, Barrera G, Kim E, Hirsch S, et al. Accuracy of a Semi-Quantitative Ultrasound Method to Determine Liver Fat Infiltration in Early Adulthood. *Diagnostics* 2020, Vol 10, Page 431. 2020 Jun 25;10(6):431.
70. Remya E, Goyal M, Varsakiya J. Efficacy of Sharapunkhadi Powder (A Polyherbal Formulation) and Lifestyle Modification in the Management of Nonalcoholic Fatty Liver Disease-A Randomized Placebo-Controlled Clinical Trial. *AYU (An Int Q J Res Ayurveda)*. 2020;41(2):98.
71. Starekova J, Hernando D, Pickhardt PJ, Reeder SB. Quantification of Liver Fat Content with CT and MRI: State of the Art. *Radiology*. 2021 Nov 1;301(2):250.
72. Nalbantoglu I, Brunt EM. Role of Liver Biopsy in Nonalcoholic Fatty Liver Disease. *World J Gastroenterol*. 2014;20(27):9026–37.
73. Sudoyo AW, Setiyohadi B, Alwi I, K MS. *Ilmu Penyakit Dalam*. keempat. Setiati S, Alwi I, Susoyo AW, Simadibrata M, Setiyohadi B, Syam FA, editors. Buku Ajar Ilmu Penyakit Dalam. 2009. 1825–1829 p.
74. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB. Physical Activity Recommendations, Exercise Intensity, and Histological Severity of Nonalcoholic Fatty Liver Disease. *Am J Gastroenterol*. 2011 Mar;106(3):460.
75. Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. *Int J Mol Sci* [Internet]. 2021 Mar 1 [cited 2023 Feb 3];22(5):1–27. Available from: </pmc/articles/PMC7956331/>

76. Raza S, Rajak S, Upadhyay A, Tewari A, Sinha RA. Current Treatment Paradigms and Emerging Therapies for NAFLD/NASH. *Front Biosci (Landmark Ed [Internet]*. 2021 Jan 1 [cited 2023 Feb 3];26(2):206. Available from: /pmc/articles/PMC7116261/
77. Kim JB, Spiegelman BM. ADD1/SREBP1 Promotes Adipocyte Differentiation and Gene Expression Linked to Fatty Acid Metabolism. *Genes Dev*. 1996;10(9):1096–107.
78. Aghakhani L, Haghghat N, Amini M, Hosseini SV, Masoumi SJ. The Risk Factors of Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients Undergoing Bariatric Surgery in Iran. *Gastroenterol Res Pract*. 2022;2022.
79. Konyn P, Alshuwaykh O, Dennis BB, Cholankeril G, Ahmed A, Kim D. Gallstone Disease and Its Association with Nonalcoholic Fatty Liver Disease, All-Cause and Cause-Specific Mortality. *Clin Gastroenterol Hepatol*. 2022;0(0).
80. Chang Y, Noh YH, Suh BS, Kim Y, Sung E, Jung HS, et al. Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study. *J Clin Med*. 2018 Nov 21;7(11).
81. Singh K, Dahiya D, Kaman L, Das A. Prevalence of Non-alcoholic Fatty Liver Disease and Hypercholesterolemia in Patients of Gallstone Disease Undergoing Laparoscopic Cholecystectomy. *Polish J Surg*. 2019;92(1):1–5.
82. Nurhikmah R, Efriza E, Abdullah D. Hubungan Peningkatan Indeks Massa Tubuh dengan Kejadian Kolelitiasis di Bagian Bedah Digestif RSI Siti Rahmah Padang Periode Januari-Juni 2018. *Heal Med J*. 2019;1(2):01–6.
83. Hayat S, Hassan Z, Changazi SH, Zahra A, Noman M, Zain ul Abdin M, et al. Comparative Analysis of Serum Lipid Profiles in Patients with and without Gallstones: A Prospective Cross-sectional study. *Ann Med Surg*. 2019;42(24):11–3.
84. de Bari O, Wang TY, Liu M, Paik CN, Portincasa P, Wang DQH. Cholesterol cholelithiasis in pregnant women: Pathogenesis, prevention and treatment. *Ann Hepatol*. 2014;13(6):728–45.
85. Liu T, Wang W, Ji Y, Wang Y, Liu X, Cao L, et al. Association between Different Combination of Measures for Obesity and New-onset Gallstone Disease. *PLoS One*. 2018;13(5):1–11.
86. Song SH, Kwon C Il, Jin SM, Park HJ, Chung CW, Kwon SW, et al. Clinical Characteristics of Acute Cholecystitis with Elevated Liver Enzymes Not Associated with Choledocholithiasis. *Eur J Gastroenterol Hepatol*. 2014;26(4):452–7.
87. Gill GK, Kaur P. Evaluation of Liver and Lipid Parameters in Cholelithiasis. *Asian J Pharm Clin Res*. 2019;12(9):64–7.

88. Florettira MT, Manawan EEU, Subandrate S. Lipid Profile of Cholelithiasis Patients at Dr. Mohammad Hoesin Central General Hospital, Palembang. *JBN (Jurnal Bedah Nasional)*. 2022;6(2):37.
89. Saha R, Bhattacharyya S, Ghosh S. A Cross Sectional Study on the Pattern and Association of Hyperlipidaemia in Patients with Cholelithiasis. *J Evol Med Dent Sci*. 2019;8(36):2807–12.
90. Kim HS, Cho SK, Kim CS, Park JS. Correction: Big data and Analysis of Risk Factors for Gallbladder Disease in the Young Generation of Korea (2019). 2019;14(3):1–13.
91. Selcuk Atamanalp S, Sait Keles M, Selim Atamanalp R, Acemoglu H, Laloglu E. The Effects of Serum Cholesterol, LDL, and HDL Levels on Gallstone Cholesterol Concentration. *Pakistan J Med Sci*. 2013;29(1):187–90.
92. Wang J, Shen S, Wang B, Ni X, Liu H, Ni X, et al. Serum lipid levels are the risk factors of gallbladder stones: A population-based study in China. *Lipids Health Dis*. 2020;19(1):1–6.
93. Siregar MH, Fatmah F, Sartika R. Analisis Faktor Utama Kadar Trigliserida Abnormal Pada Penduduk Dewasa Di Indonesia. Vol. 7, *Jurnal Delima Harapan*. 2020. p. 118–27.
94. DeFillippis A P, Blaha J M, Martin S S, Reed M R, Jones R S, Nasir K, et al. Nonalcoholic Fatty Liver Disease and serum lipoprotein: The Multi-Ethnic Study of Atherosclerosis. *Cancer Prev Res*. 201AD;6(5):477–82.
95. Lee JH, Lee HS, Cho AR, Lee YJ, Kwon YJ. Non-alcoholic fatty liver disease is an independent risk factor for LDL cholesterol target level. *Int J Environ Res Public Health*. 2021;18(7).
96. Kosekli MA, Kurtkulagi O, Kahveci G, Duman TT, Tel BMA, Bilgin S, et al. The Association between Serum Uric Acid to High Density Lipoprotein-cholesterol ratio and Non-alcoholic Fatty Liver Disease: The Abund Study. *Rev Assoc Med Bras*. 2021;67(4):549–54.
97. Alvina A. Hepatic enzyme concentrations as indicators of nonalcoholic fatty liver disease. *Universa Med*. 2016;28(3):139–45.
98. Qiu J, Kuang M, He S, Yu C, Wang C, Huang X, et al. Gender perspective on the association between liver enzyme markers and non-alcoholic fatty liver disease: insights from the general population. *Front Endocrinol (Lausanne)*. 2023;14(December):1–13.
99. Mulyono HA, Martin A, Johan J, Hadisono H. Perbedaan Rerata Kadar Serum Glutamic Pyruvate Transaminase Pada Pria Dan Wanita Penderita Non-Alcoholic Fatty Liver. *Sebatik*. 2023;27(1):355–62.

100. Tanwani BM, Jamali AA, Jamali GM, Jamali AA, Sohail MA. Non Alcoholic Fatty Liver Disease: Assessment of Lipid Profile Estimation in Different Grades of Fatty Liver on Ultrasound. *Open J Prev Med*. 2018;08(03):70–83.
101. Han JM, Kim HI, Lee YJ, Lee JW, Kim KM, Bae JC. Differing Associations between Fatty Liver and Dyslipidemia According to the Degree of Hepatic Steatosis in Korea. *J Lipid Atheroscler*. 2019;8(2):258–66.
102. Hui ZHAO, Qiu X, Li HZ, Cui JJ, Sun YY. Association between Serum Uric Acid to HDL-Cholesterol Ratio and Nonalcoholic Fatty Liver Disease Risk among Chinese Adults. *Biomed Environ Sci*. 2023;36(1):1–9.
103. Li Z, Zhang B, Liu Q, Tao Z, Ding L, Guo B, et al. Genetic Association of Lipids and Lipid-lowering Drug Target Genes with Non-alcoholic Fatty Liver Disease. *eBioMedicine*. 2023;90:104543.
104. Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. *Biochim Biophys Acta - Mol Basis Dis*. 2015;1852(9):1765–78.
105. Sinha A, Bankura B. Prevalence of nonalcoholic fatty liver disease in type 2 diabetes mellitus patients from the Eastern region of India. *Diabetes Epidemiol Manag [Internet]*. 2023;12:100161. Available from: <https://doi.org/10.1016/j.deman.2023.100161>
106. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. *Nutrients*. 2013;5(5):1544–60.

